Select Language
IL-12B
IL-12B Overview
| English Name | Interleukin-12 subunit beta | Approved Drugs | 8 |
| Drugs in Clinical Trials | 2 | Target Synonym | IL-12B，NK cell stimulatory factor chain 2，IL12B，Interleukin 12B，Interleukin 12B (Natural Killer Cell Stimulatory Factor 2， Cytotoxic Lymphocyte Maturation Factor 2， P40)，Cytotoxic Lymphocyte Maturation Factor 40 KDa Subunit，Interleukin-12 Beta Chain，Interleukin 12， P40，IL12， Subunit P40，CLMF P40，NKSF2，Cytotoxic Lymphocyte Maturation Factor 2， P40，Interleukin-12 Subunit Beta，CLMF2，IMD28，IMD29，CLMF，NKSF，Interleukin-12 Subunit p40，Natural Killer Cell Stimulatory Factor， 40 KD Subunit，IL-12 Subunit P40，Natural Killer Cell Stimulatory Factor-2 |
| Highest Development Stage | Approved | ||
| English Name | Interleukin-12 subunit beta |
| Target Synonym | IL-12B，NK cell stimulatory factor chain 2，IL12B，Interleukin 12B，Interleukin 12B (Natural Killer Cell Stimulatory Factor 2， Cytotoxic Lymphocyte Maturation Factor 2， P40)，Cytotoxic Lymphocyte Maturation Factor 40 KDa Subunit，Interleukin-12 Beta Chain，Interleukin 12， P40，IL12， Subunit P40，CLMF P40，NKSF2，Cytotoxic Lymphocyte Maturation Factor 2， P40，Interleukin-12 Subunit Beta，CLMF2，IMD28，IMD29，CLMF，NKSF，Interleukin-12 Subunit p40，Natural Killer Cell Stimulatory Factor， 40 KD Subunit，IL-12 Subunit P40，Natural Killer Cell Stimulatory Factor-2 |
| Approved Drugs | 8 |
| Drugs in Clinical Trials | 2 |
| Highest Development Stage | Approved |
IL-12B Product List
- Product Category
Protein (4)
- Product Status
Launched (4)
- Species
Human (3)Mouse (1)
- Tag
His Tag (1)Fc Tag (1)His Tag & Avi Tag (2)
- Conjugate
Unconjugated (2)Biotin-labeled (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT NK2-H82E3 |  Human | HEK293 | Biotinylated Human IL-12B / NKSF2 / p40 Protein, His,Avitag™ |  |  |  |
NK2-H5258 | Human | HEK293 | Human IL-12B / NKSF2 / p40 Protein, Fc Tag |  | | |
NK2-H52H7 | Human | HEK293 | Human IL-12B / NKSF2 / p40 Protein, His Tag |  | | |
NK2-M82E5 |  Mouse | HEK293 | Biotinylated Mouse IL-12B / NKSF2 / p40 Protein, His,Avitag™ (MALS verified) |  | | |
Total: 4
- 1
IL-12B Background
Interleukin-12 (IL12) is also known as natural killer cell stimulatory factor (NKSF), cytotoxic lymphocyte maturation factor (CLMF) , is a heterodimeric cytokine encoded by two separate genes, IL-12A (p35) and IL-12B (p40). IL12 is naturally produced by dendritic cells, macrophages and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation. IL-12 is involved in the differentiation of naive T cells into Th0 cells and plays an important role in the activities of natural killer cells and T lymphocytes.IL-12 also has anti-angiogenic activity, which means it can block the formation of new blood vessels.
Interleukin-12 subunit beta (IL12B) also known as NKSF2, CLMF2 and P40. Interleukin-12 subunit beta has been shown to interact with IL23. A large excess of monomeric IL12B is also secreted by the cells producing IL12, and exhibits no demonstrable biological activity. Overexpression of IL12B gene has been shown to be associated with the pathogenesis of multiple sclerosis. In addition, studies have revealed that the promoter polymorphism of this gene is implicated in the severity of atopic and non-atopic asthma in children.
IL-12B Synonyms
IL12B,CLMF,CLMF2,NKSF,NKSF2,p40
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| RO-7837195 | RO-7837195; RO7837195 | Phase 2 Clinical | Genentech Inc | Colitis, Ulcerative | Details |
| PF-07261271 | RG-6730; PF-07261271 | Phase 2 Clinical | Pfizer Inc | Inflammatory Bowel Diseases | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ustekinumab biosimilar (Bio-Thera) | BAT-2206 | Approved | Bio-Thera Solutions Ltd | STARJEMZA, Usymro | United States | Plaque psoriasis; Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic | Bio-Thera Solutions Ltd | 2025-05-22 | Arthritis, Psoriatic; Autoimmune Diseases; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| Ustekinumab | C-340; CNTO-1275 | Approved | Johnson & Johnson Innovative Medicine | Stelara, 喜达诺 | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Arthritis, Juvenile; Arthritis, Psoriatic; Colitis, Ulcerative; Common Variable Immunodeficiency; Crohn Disease; Dermatitis, Atopic; Dermatomyositis; Diabetes Mellitus, Type 1; Hidradenitis Suppurativa; Ichthyosis; Inflammatory Bowel Diseases; Liver Cirrhosis, Biliary; Lupus Erythematosus, Systemic; Multiple Sclerosis; Palmoplantar pustulosis; Pediatric Crohn's disease; Plaque psoriasis; Polymyositis; Pouchitis; Psoriasis; Sjogren's Syndrome; Spondylitis, Ankylosing; Takayasu Arteritis; Type I Leukocyte Adhesion Defect; Uveitis | Details |
| Ebdarokimab | AK-101; AK101 | Approved | 爱达罗 | Mainland China | Plaque psoriasis | Zhongshan Akeso Biopharma Co Ltd | 2025-04-15 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details | |
| Ustekinumab Biosimilar(Celltrion) | CT-P43 | Approved | Celltrion Inc | Steqeyma, Steqeyma IV, Qoyvolma | Canada | Arthritis, Psoriatic; Crohn Disease; Plaque psoriasis | Celltrion Inc | 2024-08-01 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| Ustekinumab biosimilar (Biocon) | Bmab 1200 | Approved | Biocon Biologics Ltd | Yesintek | United States | Colitis, Ulcerative; Crohn Disease; Arthritis, Psoriatic | Biocon Biologics Inc | 2024-11-29 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| Ustekinumab biosimilar (Alvotech) | AVT04; AVT-04 | Approved | Alvotech hf | Jamteki, Uzpruvo, SELARSDI™, JamtekiTM, Ustekinumab BS (F) | Japan | Arthritis, Psoriatic; Psoriasis | Fuji Pharma Co Ltd | 2023-09-25 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| Ustekinumab biosimilar (Samsung Bioepis) | SB-17; SB17 | Approved | Samsung Bioepis Co Ltd | Pyzchiva, Eksunbi | EU | Crohn Disease; Colitis, Ulcerative | Samsung Bioepis Nl Bv | 2024-04-19 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Gastrointestinal Diseases; Inflammation; Plaque psoriasis; Psoriasis; Rheumatic Diseases; Skin Diseases | Details |
| Ustekinumab biosimilar (Amgen) | ABP-654; AMG-654 | Approved | Amgen Inc | Wezlana, WEZLANA, wezenla, WEZENLA | United States | Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis | Amgen Inc | 2023-10-31 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland